Aerska develops targeted RNA medicines to treat brain diseases. By silencing genes that cause harm, we can preserve the minds and memories of those we love.
Location: Ireland
Total raised: $79.94M
Investors 2
| Date | Name | Website |
| 11.11.2025 | age1 | age1.com |
| 30.01.2026 | PsyMed Ven... | psymed.ven... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.02.2026 | Series A | $58.94M | EQT |
| 06.10.2025 | Seed | $21M | Ada Ventur... |
Mentions in press and media 18
| Date | Title | Description |
| 26.02.2026 | European Startups Secure Major Funding, AI Dominates, US Expansion Accelerates | European startups attract significant capital. HealthTech leads with nyra.health's €20 million for AI-powered neurological therapy. AI transforms wholesale via Plato, enterprise with VoiceLine, and model training through Rapidata. Strategic... |
| 24.02.2026 | Amid €65 billion lost each year to stroke and dementia in Germany, nyra health secures €20 million to scale digital neurotherapy | Vienna-based nyra health, a provider of an AI-based platform for neurological therapy, announces the completion of a €20 million Series A financing round to further expand its technology platform in the DACH region, accelerate its expansion... |
| 17.02.2026 | Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines | Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines... |
| 16.02.2026 | Ireland’s newest pot of gold: 10 of the most promising startups to watch in 2026 | Following our series of country deep dives, we now turn to Ireland, where Dublin has become the clear centre of gravity for the country’s newest generation of tech companies. While Ireland has long attracted multinational giants, a new coho... |
| 12.02.2026 | Aerska: $39 Million Series A Raised For Advancing Brain Shuttle RNA Medicines | Aerska, a biotechnology company developing brain shuttle technology to deliver RNA medicines to the central nervous system, has closed a $39 million Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures... |
| 10.02.2026 | Irish BioTech startup Aerska raises €32 million to “enable our loved ones to live longer” | Dublin’s Aerska, a BioTech company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a €32 million ($39 million) Series A financing to improve delivery of RNAi interference (RNAi) therape... |
| 09.02.2026 | EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain | EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain Mon, Feb 09, 2026 14:00 CET Report this content Series A financing will be used to advance Aerska’s brain shuttle technol... |
| 20.01.2026 | German BioTech Exciva lands €51 million to advance Alzheimer’s drug testing in patients | Heidelberg-based Exciva, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59 million) Series B round. Gimv and EQT Life Scien... |
| 11.01.2026 | Engitix Secures $25M to Advance Cancer, Fibrosis Therapies | British biotech innovator Engitix recently secured a significant $25 million Series A extension. Netherton Investments, acting for Mike Platt, drove this key financing. The capital fuels Engitix’s advanced extracellular matrix (ECM)-targete... |
| 08.01.2026 | London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies | Engitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing. The financing ... |
Show more